Plant Name: Cratoxylum cochinchinense
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.894E-10 | 1.426E-06 | ALOX12, ALOX15, CYP19A1, CYP2C19, CYP2C9, FASN, IDH1, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.457E-08 | 2.115E-05 | CYP19A1, CYP2C19, CYP2C9, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.468E-08 | 4.422E-05 | ALOX12, ALOX15, CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.327E-07 | 1.256E-04 | ALOX12, ALOX15, PTGS2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.181E-07 | 2.845E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 4.181E-07 | 2.845E-04 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.181E-07 | 2.845E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.254E-06 | 6.660E-04 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.254E-06 | 6.660E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.254E-06 | 6.660E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.408E-06 | 7.300E-04 | CYP19A1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.325E-06 | 1.684E-03 | CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0046890; regulation of lipid biosynthetic process | 3.626E-06 | 1.795E-03 | FASN, IDH1, NFKB1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.177E-06 | 1.935E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:2000630; positive regulation of miRNA metabolic process | 4.177E-06 | 1.935E-03 | NFKB1, RELA |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.262E-06 | 2.726E-03 | CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 6.386E-06 | 2.726E-03 | FASN, IDH1, MAPT, NFKB1, PTGS2, RELA |
| BP | GO:0032501; multicellular organismal process | GO:0045075; regulation of interleukin-12 biosynthetic process | 8.764E-06 | 3.534E-03 | NFKB1, RELA |
| CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 8.764E-06 | 3.534E-03 | NFKB1, RELA |
| BP | GO:0009987; cellular process | GO:0071316; cellular response to nicotine | 1.168E-05 | 4.542E-03 | NFKB1, RELA |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.876E-05 | 6.923E-03 | CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 2.292E-05 | 8.318E-03 | PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.749E-05 | 9.655E-03 | CYP2C19, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.168E-12 | 9.343E-11 | CYP2C9; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.477E-11 | 1.791E-09 | CYP2C9; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.446E-09 | 1.986E-07 | CYP2C9; FASN; IDH1; ALOX15; ALOX12; PTGS2; CYP2C19; CYP19A1; PTGS1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.763E-07 | 1.553E-05 | CYP2C9; ALOX15; CYP2C19 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.300E-05 | 2.080E-04 | PTGS2; RELA; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.128E-05 | 2.432E-04 | PTGS2; RELA; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.448E-05 | 3.954E-04 | PTGS2; RELA; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.844E-05 | 2.432E-04 | CYP2C9; CYP2C19; PTGS2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.691E-05 | 2.691E-04 | PTGS2; RELA; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.330E-04 | 2.959E-03 | MAPT; RELA; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.694E-04 | 2.959E-03 | PTGS2; CYP19A1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.508E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.889E-04 | 2.959E-03 | PTGS2; PTGS1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 5.680E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.100E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.172E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.100E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 7.927E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 8.672E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 7.686E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.716E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.927E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.928E-04 | 2.959E-03 | CYP2C9; CYP2C19 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.986E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.986E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.914E-03 | 4.351E-03 | PTGS2; NFKB1; RELA |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 9.187E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.899E-03 | 4.351E-03 | RELA; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.479E-03 | 3.945E-03 | RELA; NFKB1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 9.187E-04 | 2.959E-03 | RELA; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.648E-03 | 4.254E-03 | RELA; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.862E-03 | 4.351E-03 | RELA; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.054E-03 | 3.011E-03 | RELA; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.382E-03 | 3.813E-03 | RELA; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.974E-03 | 4.351E-03 | RELA; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.012E-03 | 4.351E-03 | RELA; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.089E-03 | 4.398E-03 | RELA; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.012E-03 | 4.351E-03 | RELA; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.207E-03 | 4.528E-03 | RELA; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.580E-03 | 5.080E-03 | RELA; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.667E-03 | 5.080E-03 | RELA; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.608E-03 | 6.274E-03 | RELA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.215E-03 | 5.933E-03 | RELA; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.667E-03 | 5.080E-03 | RELA; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.409E-03 | 6.060E-03 | RELA; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.916E-03 | 6.666E-03 | RELA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.263E-03 | 5.933E-03 | RELA; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.182E-03 | 6.970E-03 | RELA; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.573E-03 | 9.099E-03 | RELA; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 5.760E-03 | 9.216E-03 | RELA; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 7.358E-03 | 1.070E-02 | RELA; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.886E-03 | 9.234E-03 | RELA; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 6.338E-03 | 9.567E-03 | RELA; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 6.208E-03 | 9.550E-03 | RELA; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.571E-03 | 1.082E-02 | RELA; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.149E-03 | 1.059E-02 | RELA; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 9.213E-03 | 1.271E-02 | RELA; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.177E-02 | 1.570E-02 | RELA; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.539E-02 | 2.018E-02 | PTGS2; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.997E-02 | 2.536E-02 | RELA; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.270E-02 | 4.950E-02 | IDH1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.894E-02 | 4.650E-02 | PTGS2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.145E-02 | 4.876E-02 | CYP2C9 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.706E-02 | 4.492E-02 | CYP19A1 |
| hsa00480 | Glutathione metabolism_Homo sapiens_hsa00480 | 3.329E-02 | 4.097E-02 | IDH1 |
| hsa01212 | Fatty acid metabolism_Homo sapiens_hsa01212 | 3.076E-02 | 3.845E-02 | FASN |
| hsa00020 | Citrate cycle (TCA cycle)_Homo sapiens_hsa00020 | 1.933E-02 | 2.494E-02 | IDH1 |
| hsa01210 | 2-Oxocarboxylic acid metabolism_Homo sapiens_hsa01210 | 1.100E-02 | 1.491E-02 | IDH1 |
| hsa00061 | Fatty acid biosynthesis_Homo sapiens_hsa00061 | 8.420E-03 | 1.182E-02 | FASN |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | FASN |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | FASN |
| A00-B99: Certain infectious and parasitic diseases | Mycobacterium tuberculosis infection | A15-A19 | FASN |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; MAPT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dramatic weight loss | R63.4 | FASN |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| NA: NA | Gram-positive bacterial infection | NA | FASN |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; FASN; NFKB1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | IDH1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; NFKB1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |